Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
- There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA)1,2
- Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with GA
- Potential to be the first therapy with sustained efficacy for a broad GA patient population
- Acquisition complements Novartis established expertise in retinal diseases and gene therapy and further builds position in ophthalmology gene therapy and optogenetics following acquisitions of Vedere Bio and Arctos Medical
Basel, December 22, 2021 — Novartis announced today that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics.
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss1. There are no approved treatments for GA, making it one of the most significant unmet needs remaining in retinal diseases2.
GT005 is designed as an AAV2-based, one-time investigational gene therapy for GA secondary to AMD that is delivered under the retina. GT005 aims to restore balance to an overactive complement system, a part of the immune system, by increasing production of the CFI protein. Complement overactivation can lead to inflammation that damages healthy tissues, and it has been strongly correlated with the development and progression of AMD3. The CFI protein regulates the activity of the complement system. It is believed that increasing CFI production could reduce inflammation, with the goal of preserving a person’s eyesight.
The safety and efficacy of GT005 for the treatment of GA secondary to AMD is currently being evaluated in a Phase 1/2 clinical trial and two Phase 2 clinical trials4,5,6. GT005 has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of people with GA.
Gyroscope also has several additional assets in its pipeline in early discovery for retinal diseases.
“With our own pioneering research in ocular gene therapies and our experience gained from bringing Luxturna to inherited retinal dystrophy patients outside of the US, Novartis has a well-established expertise in ocular gene therapies that will position us well to continue developing this promising one-time treatment” said Marie-France Tschudin, President, Novartis Pharmaceuticals. “This acquisition is one more step forward in our commitment to delivering innovation in ophthalmology to treat and prevent blindness worldwide.”
Novartis will make an upfront payment of $800 million and potential additional milestone payments of up to $700 million. Closing of the transaction is subject to customary closing conditions including regulatory approvals. Until closing, Novartis and Gyroscope Therapeutics will continue to operate as separate and independent companies.
About geographic atrophy (GA)
Dry AMD is a leading cause of permanent vision loss in people over the age of 55 and is a devastating diagnosis2,7. As dry AMD advances, it leads to GA, an irreversible degeneration of retinal cells, causing a gradual and permanent loss of central vision. This disease can severely impact a person’s daily life as they lose the ability to drive, read and even see faces7.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “will,” “plan,” “could,” “commitment,” “investigational,” “to acquire,” “to develop,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for GT005, the acquisition of Gyroscope Therapeutics, or regarding potential future revenues from GT005. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that GT005 will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee expected benefits or synergies from this transaction will be achieved in the expected timeframe, or at all, nor can there be any guarantee that GT005 will be commercially successful in the future. In particular, our expectations regarding GT005 or the transaction described in this media update could be affected by, among other things, the satisfaction of customary closing conditions including regulatory approvals, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact firstname.lastname@example.org
1 Schmitz-Valckenberg S, et al. Natural History of Geographic Atrophy Progression Secondary to Age-Related Macular Degeneration (Geographic Atrophy Progression Study) Ophthalmology 2016;123:361-368.
2 National Institute of Health. “Age-Related Macular Degeneration”. Accessed December 2021. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration.
3 Holz FG, et al. Geographic Atrophy: Clinical Features and Potential Therapeutic Approaches. Ophthalmology 2014;121(5):1079-1091.
4 U.S. National Library of Medicine. “EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (EXPLORE”). Accessed December 2021. https://clinicaltrials.gov/ct2/show/NCT04437368?term=geographic+atrophy%2C+GT005&cond=Macular+Degeneration&draw=2&rank=1#contacts
5 U.S. National Library of Medicine. “HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005”. Accessed December 2021. https://clinicaltrials.gov/ct2/show/NCT04566445?term=GT005&draw=2
6 U.S. National Library of Medicine. “FocuS: First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD”. Accessed December 2021. https://clinicaltrials.gov/ct2/show/NCT03846193?term=FOCUS&cond=Geographic+Atrophy&draw=2&rank=1
7 American Macular Degeneration Foundation. “Macular Degeneration”. Accessed December 2021. https://www.macular.org/what-macular-degeneration.
# # #
Novartis Media Relations
| Amy Wolf|
Novartis External Communications
+41 79 576 0723 (mobile)
Novartis US External Communications
+1 862 579 8456
| Meghan O’Donnell|
Novartis Pharma Communications
+41 61 324 9123 (direct)
+41 79 797 9102 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 345 4440|
|Thomas Hungerbuehler||+41 61 324 8425||Alina Levchuk||+1 862 778 3372|
|Isabella Zinck||+41 61 324 7188||Parag Mahanti||+1 973-876-4912|
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
HMS Networks AB har genomfört återköp av egna aktier27.1.2022 13:07:37 CET | Pressemelding
HMS Networks AB (publ) har under perioden 26 oktober 2021 - 26 januari 2022 återköpt sammanlagt 81 000 egna aktier (ISIN SE0009997018) inom ramen för det återköpsprogram som initierats av styrelsen i syfte att säkerställa HMS åtagande att leverera prestationsaktier enligt HMS Aktiesparprogram. Det viktade genomsnittspriset för under perioden återköpta aktier uppgår till 464,22 kr per aktie. HMS Networks innehav av egna aktier uppgår efter återköpet till 238 571. Det totala antalet utestående aktier i bolaget är 46 818 868. Återköpet har genomförts på Nasdaq Stockholm. För mer information, vänligen kontakta: Staffan Dahlström, VD HMS, +46 (0)35 17 29 01 Joakim Nideborn, Finanschef HMS, +46 (0)35 710 6983 HMS Networks AB (publ) är en marknadsledande leverantör av lösningar inom industriell informations- och kommunikationsteknologi (Industrial ICT). HMS utvecklar och tillverkar produkter under varumärkena Anybus®, Ixxat®, Ewon® och Intesis®. Utveckling sker på huvudkontoret i Halmstad, sa
HMS Networks AB completes repurchase of shares27.1.2022 13:07:37 CET | Press release
HMS Networks AB (publ) has during the period October 26, 2021 – January 26, 2022, repurchased in total 81,000 own shares (ISIN SE0009997018) within the buyback program initiated by the Board of Directors in order to secure HMS’ obligations to deliver performance shares according to HMS’ Share Saving Plan. The weighted average price for the shares repurchased during the period amounts to SEK 464.22 per share. HMS Networks’ holdings of own shares amounts to 238,571 after the repurchase. The total number of outstanding shares in the company is 46,818,868. The repurchase has been made on Nasdaq Stockholm. For more information, please contact: Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01 Joakim Nideborn, CFO HMS, +46 (0)35 710 6983 HMS Networks AB (publ) is a market-leading provider of solutions in industrial information and communication technology (Industrial ICT). HMS develops and manufactures products under the Anybus®, Ixxat®, Ewon® and Intesis® brands. Development takes place at the
2021 preliminary revenue result exceeds guidance27.1.2022 13:03:14 CET | Press release
COMPANY ANNOUNCEMENT NO. 1-2022 27 January 2022, Copenhagen, Denmark Full year 2021 preliminary revenue exceeds latest financial guidance provided on 11 November 2021 in Company Announcement No. 17-2021. This was primarily driven by the Capital business in Q4 2021. Preliminary and unaudited key figures for Q4 and full year 2021 Q4 2021FY 2021FY 2021 guidanceRevenue (DKK bn)5.117.616.0-17.0EBITA margin6.6%5.9%5-6% The Q4 and full year 2021 results include costs related to the thyssenkrupp Mining acquisition of around DKK 37m and around DKK 107m, respectively. Subject to regulatory approval, closing of the transaction is still expected in the second half of 2022. FLSmidth will, as previously communicated, release the detailed and audited financial results for the full year of 2021 on 16 February 2022. Contacts: Investor Relations Jannick Lindegaard Denholt, +45 21 69 66 57, email@example.com Therese Möllevinge, +45 41 37 16 38, firstname.lastname@example.org Mikkel Johansen, +45 23 30 29 50, mjoh@flsmi
Inbjudan till presentation av Sdiptechs Bokslutskommuniké för 202127.1.2022 13:00:00 CET | Pressemelding
Inbjudan till presentation av Sdiptechs Bokslutskommuniké för 2021 Sdiptech AB (publ) offentliggör sin Bokslutskommuniké 2021 torsdagen den 10 februari 2022, kl. 08:00, och bjuder in till en presentation via en webbsänd telefonkonferens samma dag kl. 14.00. Sdiptechs VD Jakob Holm och CFO Bengt Lejdström kommer att presentera rapporten samt svara på frågor. Presentationen hålls på engelska. Presentationen webbsänds Sändningen går att följa via följande länk: https://www.finwire.tv/webcast/sdiptech/q4-2021/ De presentationsbilder som används kommer att finnas tillgängliga under webbsändningen och kommer även att publiceras på bolagets hemsida, www.sdiptech.se, innan presentationen. För ytterligare information, vänligen kontakta: Bengt Lejdström, CFO, +46 702 74 22 00, email@example.com My Lundberg, Sustainability & IR Manager, +46 703 61 18 10, firstname.lastname@example.org Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 27 januari 2022 k
Invitation to presentation of Sdiptech’s Year-End Report for 202127.1.2022 13:00:00 CET | Press release
Invitation to presentation of Sdiptech’sYear-End Reportfor 2021 Sdiptech AB (publ) will publish its interim report for the Year-End Report 2021 on Thursday, 10 February 2022 at 08:00 CET and invites you to a presentation via a webcast conference call on the same date at 14.00 CET. Sdiptech's CEO Jakob Holm and CFO Bengt Lejdström will present the report and answer questions. The presentation will be held in English. Webcast presentation The transmission can be viewed via the following link: https://www.finwire.tv/webcast/sdiptech/q4-2021/ The presentation slides used will be available during the webcast and will be published on the company's website, www.sdiptech.se, before the start of the presentation. For further information, please contact: Bengt Lejdström, CFO, +46 702 74 22 00, email@example.com My Lundberg, Sustainability & IR Manager, +46 703 61 18 10, firstname.lastname@example.org The information was sent for publication, through the agency of the contact person set out
Share Buyback Transaction Details January 20 – 26, 202227.1.2022 10:00:00 CET | Press release
Share Buyback Transaction Details January 20 – 26, 2022 January 27, 2022 - Wolters Kluwer today reports that it has repurchased 78,099 of its own ordinary shares in the period from January 20, 2022, up to and including January 26, 2022, for €6.9 million and at an average share price of €88.92. These repurchases are part of the share buyback program announced on November 3, 2021, under which we intend to repurchase shares for €50 million during the period starting January 3, 2022, up to and including February 21, 2022. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2022 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€) 2022 to date 265,483 25.0 94.18 For the above-mentioned period, we have engaged a third party to execute €50 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association.
Cool Company Limited Update27.1.2022 09:14:12 CET | Press release
27 January 2022; Golar LNG (“Golar”) is pleased to provide a further update on the formation of Cool Company Ltd. (“CoolCo”). Reference is made to announcements on 15 December 2021 and 20 January 2022, regarding Golar’s announced execution of a Terms Agreement to separate its 8 TFDE LNG carriers into CoolCo. Based on investor feedback following the press releases made on 15 December 2021 and 20 January 2022, CoolCo has decided to launch a book building process of a private placement of $250 million (“The Private Placement”). The anticipated proceeds from the Private Placement will, together with a contemplated debt refinancing, be used to finance the acquisition of the 8 TFDE vessels from Golar, secure attractive financing and provide CoolCo with working capital to position the company for further growth. Eastern Pacific Shipping (“EPS”) has pre-subscribed and guaranteed an allocation of minimum $150 million in the contemplated private placement. The Private Placement The Private Place